Shares of PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) have received an average recommendation of “Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $13.00.
Several equities analysts recently weighed in on PHAS shares. Zacks Investment Research downgraded PhaseBio Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Citigroup raised their price target on PhaseBio Pharmaceuticals from $11.00 to $12.00 in a research report on Friday, May 29th. Needham & Company LLC began coverage on shares of PhaseBio Pharmaceuticals in a research report on Thursday, May 28th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Stifel Nicolaus restated a “buy” rating and set a $4.00 target price on shares of PhaseBio Pharmaceuticals in a report on Tuesday, May 5th.
Several large investors have recently modified their holdings of the company. Wedbush Securities Inc. acquired a new stake in shares of PhaseBio Pharmaceuticals during the second quarter valued at $52,000. Wells Fargo & Company MN boosted its stake in shares of PhaseBio Pharmaceuticals by 107.0% during the 1st quarter. Wells Fargo & Company MN now owns 16,832 shares of the company’s stock worth $55,000 after purchasing an additional 8,699 shares during the last quarter. UBS Group AG grew its holdings in shares of PhaseBio Pharmaceuticals by 39.8% during the fourth quarter. UBS Group AG now owns 18,059 shares of the company’s stock worth $110,000 after buying an additional 5,139 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of PhaseBio Pharmaceuticals by 16.1% in the first quarter. Bank of New York Mellon Corp now owns 41,251 shares of the company’s stock valued at $136,000 after buying an additional 5,732 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of PhaseBio Pharmaceuticals by 7.7% during the second quarter. First Trust Advisors LP now owns 30,008 shares of the company’s stock valued at $138,000 after buying an additional 2,133 shares during the period. Institutional investors and hedge funds own 64.29% of the company’s stock.
NASDAQ:PHAS opened at $4.00 on Tuesday. The firm’s fifty day simple moving average is $4.79 and its 200-day simple moving average is $4.50. The company has a quick ratio of 9.68, a current ratio of 9.68 and a debt-to-equity ratio of 0.23. PhaseBio Pharmaceuticals has a fifty-two week low of $2.60 and a fifty-two week high of $9.82.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). PhaseBio Pharmaceuticals had a negative return on equity of 70.50% and a negative net margin of 2,310.60%. The company had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.38 million. As a group, analysts forecast that PhaseBio Pharmaceuticals will post -2.01 EPS for the current year.
About PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.
Read More: Initial Coin Offering (ICO)
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.